GlassScriptPhysician profile
Danielle Amisano
NPI 1164951539
$2,003.19
in general payments reported to CMS, 2019-2025
27 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.73 · 2022: $334 · 2023: $929 · 2024: $198 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $226.66 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Procept Biorobotics Corporation | $186.45 | 2023 | Aquabeam Robotic System |
| Apollo Endosurgery US INC | $149.20 | 2023 | Overstitch Endoscopic Suturing System |
| Merck Sharp & Dohme LLC | $146.42 | 2021-2023 | Verquvo, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $139.98 | 2023-2025 | |
| Thd America, INC. | $133.07 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $121.62 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $119.88 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $114.17 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.39 | 2021-2024 | Ofev, Stiolto Respimat |
| Amgen INC. | $101.46 | 2022-2023 | Tezspire |
| Baxter Healthcare | $51.01 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Janssen Pharmaceuticals, INC | $47.58 | 2022-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $43.05 | 2021-2022 | |
| Amarin Pharma, INC. | $40.57 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.36 | 2025 | |
| Almatica Pharma LLC | $28.29 | 2025 | Teriparatide |
| Vertex Pharmaceuticals Incorporated | $26.59 | 2025 | |
| Genzyme Corporation | $24.83 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $24.80 | 2023 | Opsumit |
| Exact Sciences Corporation | $21.87 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $21.34 | 2025 | Zepbound |
| Dynavax Technologies Corporation | $20.46 | 2022 | |
| Dexcom, INC. | $18.03 | 2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $17.82 | 2025 | Contrave |
| Daiichi Sankyo INC. | $15.63 | 2023 | Injectafer |
| Philips North America LLC | $14.66 | 2024 | (Ck7) Extended Holter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Amisano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.